SAPO

Jorge Nice, Quinta do Bill, DJ Monchique e fogo-de-artifício. Já sabemos o programa da Passagem de Ano em Setúbal

Para muitos foliões, o réveillon é considerada a noite mais aguardada do ano, o momento em que nos despedimos do ano velho e, ...
SAPO

Alfa Romeo: A fábrica de Arese

A fábrica de Arese, em Milão, foi uma das mais importantes para a Alfa Romeo, sendo o seu centro de operações até 1986. Foi a ...
Diário de Notícias on MSN

Fórmula 1. FIA vem fazer vistoria ao Autódromo do Algarve no próximo dia 22 de dezembro

A data do regresso do Grande Prémio de Portugal ainda não foi anunciada e só o será quando se definir o calendário das corridas para 2027, ou seja, a meio do próximo ano. Tudo indica que poderá ser du ...
eco.sapo

De Braga a Sintra, a greve geral ‘dividiu’ um país a meio gás

A paralisação convocada pela CGTP e UGT encerrou muitos estabelecimentos públicos, mas os serviços mínimos foram cumpridos nos transportes e até houve escolas e hospitais a funcionar. O dia 11 de ...
Yahoo Finance

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative ...

ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
Yahoo Finance

Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia

RMAT designation indicates that SENTI-202 has the potential to address unmet medical needs for patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) based on preliminary clinical ...
Benzinga.com

Why Is Gene Therapy Focused Senti Bio Stock Falling Today?

Data from 20 patients (18 with evaluable responses) were presented at the American Society of Hematology (ASH) Annual Meeting. On Tuesday, the U.S. Food and Drug Administration (FDA) granted ...
Investing

Senti Bio stock soars after positive cancer therapy trial results

Investing.com -- Senti Biosciences (NASDAQ:SNTI) stock surged 29% after the company reported positive clinical trial results for its cancer therapy SENTI-202 and received FDA Regenerative Medicine ...
MarketWatch

Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative ...

The MarketWatch News Department was not involved in the creation of this content. -- ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 ...
Nasdaq

Senti Biosciences Announces Positive Data From Ongoing SENTI-202 Trial, Stock Up

(RTTNews) - Senti Biosciences, Inc. (SNTI), Tuesday announced new data from its ongoing trial of SENTI-202, evaluating the safety, efficacy, and pharmacodynamics of ...